問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Neurology

更新時間：2023-09-19

呂榮國
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

呂榮國

List

29Cases

2017-07-01 - 2020-06-09

Phase III

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia

  • Condition/Disease

    Trigeminal Neuralgia

  • Test Drug

    BIIB074

Participate Sites
5Sites

Not yet recruiting5Sites

2021-11-01 - 2027-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-02-01 - 2021-09-15

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis.

  • Condition/Disease

    generalized myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Recruiting5Sites

郭育呈
China Medical University Hospital

Division of Neurology

2020-05-01 - 2021-12-27

Phase III

A randomized, open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis

  • Condition/Disease

    myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting1Sites

Study ended1Sites

2021-02-03 - 2024-01-25

Phase III

An open-label extension study to evaluate rozanolixizumab in study participants with generalized myasthenia gravis

  • Condition/Disease

    generalized myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting1Sites

Study ended1Sites

2009-01-01 - 2014-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-02-01 - 2020-05-30

Phase III

A 12-week double-blind, randomized, multi-center study comparing the efficacy and safety of once monthly subcutaneous AMG 334 against placebo in adult episodic migraine patients (EMPOwER)

  • Condition/Disease

    Episodic Migraine

  • Test Drug

    AMG334

Participate Sites
9Sites

Terminated8Sites

Study ended1Sites

林剛旭
China Medical University Hospital

羅榮昇
Linkou Chang Gung Medical Foundation

2019-01-02 - 2019-12-31

Phase II

A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia

  • Condition/Disease

    Post-herpetic Neuralgia

  • Test Drug

    EMA401 (Olodanrigan)

Participate Sites
4Sites

Terminated4Sites

2021-04-01 - 2026-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB